Investors in Capricor Therapeutics Urged to Act Before Class Action Deadline

Overview of Capricor Therapeutics and Class Action Notice

Capricor Therapeutics, Inc. is currently in a challenging situation as investors scramble to address significant financial setbacks. Following the latest news from Hagens Berman Sobol Shapiro LLP, investors have been alerted about a potential class action lawsuit against the company, alongside a reminder of the approaching deadline to act before September 28, 2026. This alert caters specifically to those who have experienced substantial losses linked to their investment in Capricor, particularly concerning their lead product candidate, Deramiocel.

Significant Events Leading to Investor Losses

The FDA's recent decision to extend the review period for Capricor's Biologics License Application (BLA) has raised red flags among investors. Originally set for a decision by August 22, 2026, the new target action date is now November 22, 2026. This delay has resulted from prior discussions where critical data related to the FDA's evaluation was found to be misleading. The extension also follows a tumultuous Advisory Committee meeting in July, adding to the scrutiny surrounding Capricor's operations.

On December 3, 2025, the company had celebrated positive outcomes from its Phase 3 HOPE-3 study, leading to a dramatic increase in its stock price of 370% shortly following the announcement. However, subsequent briefing documents revealed alleged inconsistencies and misleading statements regarding clinical trial data and the statistical analysis plan (SAP), leading to a significant 64% drop in stock value on July 27, 2026, the day after these findings became public.

Core Allegations in the Class Action Lawsuit

The class action lawsuit filed claims that Capricor and its executives have been less than forthcoming regarding the efficacy endpoints of Deramiocel. Specifically, it alleges that crucial changes to the SAP were made without proper agreement from the FDA, casting doubt on the validity of the previously reported positive trial results.

The Hagens Berman firm is closely investigating these claims and is focused on understanding how the management characterized the clinical data that led to these investor losses. The legal firm is calling for those who have suffered losses during the class period from December 17, 2025 to July 26, 2026, to come forward as potential lead plaintiffs.

What Affected Investors Should Do

Those who have purchased shares of Capricor Therapeutics during the specified time period and experienced significant financial damage should consider filing to become lead plaintiffs in the lawsuit. It is essential to act swiftly, as the deadline to lead this class action is rapidly approaching.

Furthermore, even if investors choose not to seek lead status, they can still participate in any potential recovery. Hagens Berman also welcomes information from whistleblowers who may have non-public data on Capricor’s activities, potentially aiding in the investigation and legal proceedings. It is noted that whistleblowers could be eligible for rewards based on the SEC’s effective programs.

Conclusion

The situation surrounding Capricor Therapeutics remains fluid, and investors are urged to stay informed and act promptly. The impending deadline signifies the urgency in addressing their legal rights concerning the stock's substantial decline. For ongoing updates, investors are encouraged to visit Hagens Berman’s dedicated webpage and follow their official channels for the latest developments on this class action lawsuit.